Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00083824 · ClinicalTrials.gov registry record · Phase 2
Estrogen, HDL, and Coronary Heart Disease in Women
A Phase 2 study of Cardiovascular Diseases and Heart Diseases, sponsored by Tufts University.
- Completed
- Registry status
- Phase 2
- Development phase
- 309
- Enrollment target
- 1
- Study location
NCT00083824 is a Phase 2 study of Cardiovascular Diseases and Heart Diseases that has completed, run by Tufts University. The registered enrollment target is 309 participants, below the 26,973-participant average among 300 other Cardiovascular Diseases trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00083824, a Phase 2 study of Cardiovascular Diseases and Heart Diseases, has completed, sponsored by Tufts University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 309 participants
- Enrollment target
- 1
- Study location
Study Summary
To clarify the effects of estrogen, with or without progestin, on high density lipoprotein (HDL) in postmenopausal women.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Medroxyprogesterone 17-Acetate
- DRUG Estrogens, Conjugated (USP)
Study Locations (1)
Massachusetts
- HNRCA at Tufts University - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 309 participants |
| Start Date | 2004-03 |
| Est. Completion | 2007-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00083824
The ClinicalTrials.gov registry entry for NCT00083824 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 309 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 26,973-participant average among 300 other Cardiovascular Diseases trials with a reported enrollment target (99% lower). The listed sponsor is Tufts University, which has 163 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Cardiovascular Diseases appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT00083824 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT00083824 about?
NCT00083824 is a clinical study titled "Estrogen, HDL, and Coronary Heart Disease in Women". To clarify the effects of estrogen, with or without progestin, on high density lipoprotein (HDL) in postmenopausal women.
What is the current status of trial NCT00083824?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 309 participants. The study started on 2004-03. Estimated completion is 2007-02.
What conditions does trial NCT00083824 study?
This clinical trial studies the following conditions: Cardiovascular Diseases, Heart Diseases, Coronary Disease, Coronary Arteriosclerosis.
What interventions are being tested in trial NCT00083824?
The interventions under investigation include: Placebo (DRUG), Medroxyprogesterone 17-Acetate (DRUG), Estrogens, Conjugated (USP) (DRUG).
Who is sponsoring clinical trial NCT00083824?
This trial is sponsored by Tufts University, which has 163 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00083824 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cardiovascular Diseases
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
NAUTICAL: Effect of Natriuretic Peptide Augmentation on Cardiometabolic Health in Black Individuals
RECRUITING · Phase 2
-
Emergency Medicine Cardiovascular Risk Assessment for Lipid Disorders Trial
RECRUITING · Phase 2
-
A Study of Mosliciguat in Combination With Inhaled Treprostinil in PH-ILD
RECRUITING · Phase 2
-
Omega-3D: Omega-3 for Diet-Driven Health Disparities
RECRUITING · Phase 2
-
Microbiome Metabolites and Alcohol in HIV to Reduce CVD RCT
RECRUITING · Phase 2
-
Virtual Care Strategies to Improve Participation in Cardiac Rehabilitation Among Veterans
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.